Plasma Exchange And Glucocorticoids In ANCA Associated Vasculitis: A Randomised Controlled Trial (PEXIVAS Australia)
Funder
National Health and Medical Research Council
Funding Amount
$635,243.00
Summary
Vasculitis is a life-threatening disease, and the current treatment for this condition is not satisfactory. This clinical trial aims to determine 1) if plasma exchange can lower mortality and the development of severe kidney failure due to this disease, and 2) if the use of lower doses of corticosteroids can lessen the infectious complications of treatment. This trial is part of a major international effort which will involve a total of 500 patients from Australia, UK, Europe, USA and NZ.
Plasma Exchange And Glucocorticoids In Anti-neutrophil Cytoplasm Antibody Associated Systemic Vasculitis: A Randomised Controlled Trial (PEXIVAS Australia)
Funder
National Health and Medical Research Council
Funding Amount
$420,110.00
Summary
ANCA-associated vasculitis is a life-threatening disease. The PEXIVAS trial will investigate whether plasma exchange, in addition to immunosuppressive therapy and glucocorticoids, will reduce death and the development of severe kidney failure due to this disease. Additionally, the project will also look at whether using a reduced dose of glucocorticoids is just as effective as larger doses in lessening the infectious complications of treatment.
The Beta-blocker To LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study
Funder
National Health and Medical Research Council
Funding Amount
$597,811.00
Summary
The BLOCADE Feasibility Study aims to find out what is needed for a study to see if the drug carvedilol reduces heart disease events in people who need kidney dialysis. Carvedilol is widely used to treat the types of heart disease that are common in people on dialysis but the nature of dialysis may lead to more side effects or to less benefit. A Feasibility Study must be done first to properly plan a large study of carvedilol in people on dialysis that answers this important question.
Canadian-Australasian Randomised Trial Of Screening Kidney Transplant Recipients For Coronary Artery Disease (CARSK Study)
Funder
National Health and Medical Research Council
Funding Amount
$1,223,933.00
Summary
Patients waitlisted for kidney transplantation are at increased risk of heart attack and routinely undergo tests every year to screen for heart disease. This may lead to excessive tests, inconvenience, cost and missed opportunities for transplantation. This randomised trial will determine whether such testing is necessary and what it costs to patients and the health system. The results will have implications for tens of thousands of patients worldwide.
The PRESERVE Trial: Prevention Of Serious Adverse Events Following Angiography
Funder
National Health and Medical Research Council
Funding Amount
$2,424,334.00
Summary
More than 75,000 coronary angiograms are performed each year in Australia. The dye used in angiograms can cause acute kidney injury (AKI); with diabetes, pre-existing kidney disease and heart failure putting people at high risk. Consequences include irreversible kidney failure requiring dialysis and risk of death. Little evidence support currently used prevention strategies. The PRESERVE Trial will recruit 5,200 people to provide definitive evidence to guide prevention of AKI.
IgA nephropathy is one of the most common causes of kidney failure in Australia and around the world, but there are currently no specific treatments proven to prevent kidney failure. The SIGNAL trial, jointly led by Australian and Chinese researchers, will bring together leading experts from around the world to reliably ascertain the effects of steroid therapy in this condition, and could potentially prevent many people from developing kidney failure in the future.
Understanding And Optimising The Delivery Of Chronic Disease Care For Better Cardiovascular Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$483,402.00
Summary
The proposed research program will undertake research that utilises existing clinical information and structures. This information will provide evidence in a cost effective manner. A particular project will examine current treatment delivered to people with chronic disease. A second project will embed a study of the optimum level of sodium exposure in dialysis within routine clinical practice. The outcome will be a cost-efficient study that will potentially lead to improve outcomes.
The Australasian Kidney Trials Network will facilitate well-conducted clinical research and foster collaboration between leading researchers in kidney disease. The Network�s focus will be to answer important questions about prevention and treatment of kidney disease to improve health and quality of life outcomes. The Network will be at the forefront of knowledge creation and address complex economic, technological and social needs relating to the patient care and the translation of research into ....The Australasian Kidney Trials Network will facilitate well-conducted clinical research and foster collaboration between leading researchers in kidney disease. The Network�s focus will be to answer important questions about prevention and treatment of kidney disease to improve health and quality of life outcomes. The Network will be at the forefront of knowledge creation and address complex economic, technological and social needs relating to the patient care and the translation of research into clinical practice.Read moreRead less